NBP24519900
CA19-9/Sialyl Lewis A Antibody (SPM588), Novus Biologicals™
Manufacturer: Fischer Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | NBP24519900-Each-of-1 | In Stock | ₹ 22,930.08 |
NBP24519900 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 22,930.08
GST (18%): ₹ 4,127.414
Total Price: ₹ 27,057.494
Antigen
CA19-9/Sialyl Lewisa
Classification
Monoclonal
Concentration
0.2mg/mL
Dilution
Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 0.5 - 1.0 ug/ml
Host Species
Mouse
Purification Method
Protein A or G purified
Regulatory Status
RUO
Test Specificity
CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This MAb is superb for staining of formalin-fixed, paraffin-embedded tissues.
Content And Storage
Store at 4C.
Isotype
IgM κ
Applications
Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence
Clone
SPM588
Conjugate
Unconjugated
Formulation
10mM PBS and 0.05% BSA with 0.05% Sodium Azide
Immunogen
Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le).
Quantity
0.02 mg
Primary or Secondary
Primary
Target Species
Human
Form
Purified
Related Products
Description
- Ensure accurate, reproducible results in Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence CA19-9/Sialyl Lewis A Monoclonal specifically detects CA19-9/Sialyl Lewis A in Human samples
- It is validated for Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunofluorescence.
Compare Similar Items
Show Difference
Antigen: CA19-9/Sialyl Lewisa
Classification: Monoclonal
Concentration: 0.2mg/mL
Dilution: Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 0.5 - 1.0 ug/ml
Host Species: Mouse
Purification Method: Protein A or G purified
Regulatory Status: RUO
Test Specificity: CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This MAb is superb for staining of formalin-fixed, paraffin-embedded tissues.
Content And Storage: Store at 4C.
Isotype: IgM κ
Applications: Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence
Clone: SPM588
Conjugate: Unconjugated
Formulation: 10mM PBS and 0.05% BSA with 0.05% Sodium Azide
Immunogen: Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le).
Quantity: 0.02 mg
Primary or Secondary: Primary
Target Species: Human
Form: Purified
Antigen:
CA19-9/Sialyl Lewisa
Classification:
Monoclonal
Concentration:
0.2mg/mL
Dilution:
Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 0.5 - 1.0 ug/ml
Host Species:
Mouse
Purification Method:
Protein A or G purified
Regulatory Status:
RUO
Test Specificity:
CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This MAb is superb for staining of formalin-fixed, paraffin-embedded tissues.
Content And Storage:
Store at 4C.
Isotype:
IgM κ
Applications:
Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence
Clone:
SPM588
Conjugate:
Unconjugated
Formulation:
10mM PBS and 0.05% BSA with 0.05% Sodium Azide
Immunogen:
Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le).
Quantity:
0.02 mg
Primary or Secondary:
Primary
Target Species:
Human
Form:
Purified
Antigen: CA19-9/Sialyl Lewisa
Classification: Monoclonal
Concentration: 0.2mg/mL
Dilution: Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 0.5 - 1.0 ug/ml
Host Species: Mouse
Purification Method: Protein A or G purified
Regulatory Status: RUO
Test Specificity: CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This MAb is superb for staining of formalin-fixed, paraffin-embedded tissues.
Content And Storage: Store at 4C.
Isotype: IgM κ
Applications: Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence
Clone: SPM588
Conjugate: Unconjugated
Formulation: 10mM PBS and 0.05% BSA with 0.05% Sodium Azide
Immunogen: Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le).
Quantity: 0.1 mg
Primary or Secondary: Primary
Target Species: Human
Form: Purified
Antigen:
CA19-9/Sialyl Lewisa
Classification:
Monoclonal
Concentration:
0.2mg/mL
Dilution:
Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 0.5 - 1.0 ug/ml
Host Species:
Mouse
Purification Method:
Protein A or G purified
Regulatory Status:
RUO
Test Specificity:
CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This MAb is superb for staining of formalin-fixed, paraffin-embedded tissues.
Content And Storage:
Store at 4C.
Isotype:
IgM κ
Applications:
Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence
Clone:
SPM588
Conjugate:
Unconjugated
Formulation:
10mM PBS and 0.05% BSA with 0.05% Sodium Azide
Immunogen:
Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le).
Quantity:
0.1 mg
Primary or Secondary:
Primary
Target Species:
Human
Form:
Purified
Antigen: CA19-9/Sialyl Lewisa
Classification: Monoclonal
Concentration: 0.2mg/mL
Dilution: Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 0.5 - 1.0 ug/ml
Host Species: Mouse
Purification Method: Protein A or G purified
Regulatory Status: RUO
Test Specificity: CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This MAb is superb for staining of formalin-fixed, paraffin-embedded tissues.
Content And Storage: Store at 4C.
Isotype: IgM κ
Applications: Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence
Clone: SPM588
Conjugate: Unconjugated
Formulation: 10mM PBS and 0.05% BSA with 0.05% Sodium Azide
Immunogen: Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le).
Quantity: 0.2 mg
Primary or Secondary: Primary
Target Species: Human
Form: Purified
Antigen:
CA19-9/Sialyl Lewisa
Classification:
Monoclonal
Concentration:
0.2mg/mL
Dilution:
Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 0.5 - 1.0 ug/ml
Host Species:
Mouse
Purification Method:
Protein A or G purified
Regulatory Status:
RUO
Test Specificity:
CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This MAb is superb for staining of formalin-fixed, paraffin-embedded tissues.
Content And Storage:
Store at 4C.
Isotype:
IgM κ
Applications:
Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence
Clone:
SPM588
Conjugate:
Unconjugated
Formulation:
10mM PBS and 0.05% BSA with 0.05% Sodium Azide
Immunogen:
Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le).
Quantity:
0.2 mg
Primary or Secondary:
Primary
Target Species:
Human
Form:
Purified
Antigen: IPO-38
Classification: Monoclonal
Concentration: 0.2mg/mL
Dilution: Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 0.5 - 1.0 ug/ml
Host Species: Mouse
Purification Method: Protein A or G purified
Regulatory Status: RUO
Test Specificity: Recognizes a protein of 14-16kDa, which is a novel nuclear antigen of proliferating cells. IPO-38 antigen is present in the nuclei of proliferating cells such as Hodgkin s disease and non-Hodgkin s lymphomas, different forms of leukemias, breast and colorectal carcinomas, and PHA-stimulated lymphocytes. It is not expressed in the cells of non-stimulated lymphocytes and granulocytes. IPO-38 can be a useful marker of cell proliferation during monitoring of tumor progression.
Content And Storage: Store at 4C.
Isotype: IgM κ
Applications: Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence
Clone: SPM260
Conjugate: Unconjugated
Formulation: 10mM PBS and 0.05% BSA with 0.05% Sodium Azide
Immunogen: Spleen cells of a patient with hairy cell leukemia
Quantity: 0.02 mg
Primary or Secondary: Primary
Target Species: Human, Mouse, Rat
Form: Purified
Antigen:
IPO-38
Classification:
Monoclonal
Concentration:
0.2mg/mL
Dilution:
Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 0.5 - 1.0 ug/ml
Host Species:
Mouse
Purification Method:
Protein A or G purified
Regulatory Status:
RUO
Test Specificity:
Recognizes a protein of 14-16kDa, which is a novel nuclear antigen of proliferating cells. IPO-38 antigen is present in the nuclei of proliferating cells such as Hodgkin s disease and non-Hodgkin s lymphomas, different forms of leukemias, breast and colorectal carcinomas, and PHA-stimulated lymphocytes. It is not expressed in the cells of non-stimulated lymphocytes and granulocytes. IPO-38 can be a useful marker of cell proliferation during monitoring of tumor progression.
Content And Storage:
Store at 4C.
Isotype:
IgM κ
Applications:
Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence
Clone:
SPM260
Conjugate:
Unconjugated
Formulation:
10mM PBS and 0.05% BSA with 0.05% Sodium Azide
Immunogen:
Spleen cells of a patient with hairy cell leukemia
Quantity:
0.02 mg
Primary or Secondary:
Primary
Target Species:
Human, Mouse, Rat
Form:
Purified